Biomea Fusion, Inc. (BMEA) stock
BMEANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.58+0.02 (+3.47%)
Close on Nov 13, 2026Market cap $42.20MP/E –Yield –
Biomea Fusion free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Biomea Fusion's free cash flow for the twelve months ending Sep 30, 2025 was -$86.52M. For fiscal 2024 it was -$120.26M. The highest annual figure on record is -$4.51M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$120.26M | – |
| FY2023 | Dec 31, 2023 | -$99.96M | – |
| FY2022 | Dec 31, 2022 | -$63.45M | – |
| FY2021 | Dec 31, 2021 | -$38.61M | – |
| FY2020 | Dec 31, 2020 | -$4.51M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$11.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.67M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.09M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.07M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.85M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.94M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.23M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.70M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.19M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.03M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.25M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.78M | – |
See a number that looks wrong?